Antiviral drug resistance is a crucial factor that frequently determines the success of long-term therapy for chronic hepatitis B. The development of resistance to nucleos(t)ide analogues has been associated with exacerbations in liver disease and increased risk of emergence of multidrug resistance. The selection of a potent nucleos(t)ide analogue with a high barrier to resistance as a first-line therapy, such as entecavir or tenofovir, provides the best chance of achieving long-term treatment goals and should be used wherever possible.
Go to Source
Similar Products: Powered by 
 |
Hepatitis C: Antiviral Drug Discovery and Development :: Amazon The hepatitis C virus (HCV) is a significant public health problem of international importance. HCV is capable of establishing chronic infec |
 |
Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future :: Amazon Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our unders |
Related posts:
- Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations
- [Review] HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review
- High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo
- [Articles] Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study
- [Articles] HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
